Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.71 -7.51% -0.22
BLCM closed down 7.51 percent on Monday, May 20, 2019, on 1.44 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BLCM trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish -7.51%
180 Bearish Setup Bearish Swing Setup -7.51%
Bollinger Band Squeeze Range Contraction -7.51%
Crossed Above 20 DMA Bullish -11.73%
Pocket Pivot Bullish Swing Setup -11.73%

Older signals for BLCM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Medicine Cancer Clinical Medicine Immunotherapy Solid Tumors Cancer Treatments Prostate Cancer Virotherapy Vaccination Melanoma Immunotherapies Cell Therapy Transplantation Kite Pharma Cancer Vaccine Hematological Cancers Chimeric Antigen Receptor Treatment Of Hematological Cancers Treatment Of Various Forms Of Cancer
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.26
52 Week Low 2.7
Average Volume 417,840
200-Day Moving Average 4.3037
50-Day Moving Average 3.3134
20-Day Moving Average 3.026
10-Day Moving Average 2.978
Average True Range 0.2003
ADX 15.02
+DI 14.0986
-DI 23.8974
Chandelier Exit (Long, 3 ATRs ) 2.7291
Chandelier Exit (Short, 3 ATRs ) 3.3009
Upper Bollinger Band 3.2704
Lower Bollinger Band 2.7816
Percent B (%b) -0.15
BandWidth 16.153338
MACD Line -0.1222
MACD Signal Line -0.1062
MACD Histogram -0.016
Fundamentals Value
Market Cap 90.04 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -0.92
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.00
Resistance 3 (R3) 3.02 2.96 2.95
Resistance 2 (R2) 2.96 2.88 2.94 2.93
Resistance 1 (R1) 2.83 2.84 2.80 2.81 2.92
Pivot Point 2.77 2.77 2.75 2.75 2.77
Support 1 (S1) 2.64 2.69 2.61 2.62 2.50
Support 2 (S2) 2.58 2.65 2.56 2.49
Support 3 (S3) 2.45 2.58 2.47
Support 4 (S4) 2.43